Purpose [18F]Fluorodeoxyglucose (FDG) is widely used in PET/CT imaging to detect large vessel vasculitis in giant cell arteritis (GCA), but its performance is suboptimal in patients receiving glucocorticoids. We aimed to compare [68Ga]Ga-HA-DOTA-TATE, a somatostatin 2-analogue tracer, to [18F]FDG in a pilot study of patients with GCA. Methods Eight patients with active GCA were prospectively, sequentially scanned with both [18F]FDG PET/CT and [68Ga]Ga-HA-DOTA-TATE PET/CT imaging. Images were evaluated by 2 blinded nuclear medicine specialists. Tracer uptake was assessed in 8 vascular territories using SUVmax, and target-background ratios (TBR) were calculated using both right atrium (TBRRA) and liver mean (TBRliver). Mean SUVmax and TBR of individual vascular territories and index vessels were compared. Results The patient median age was 71.5 years (range 64–82), and 4 (50%) were women. Active vasculitis (≥ grade 2 visual uptake in large vessels) was present in 62.5% of [18F]FDG scans. [18F]FDG scans had higher RA background activity than [68Ga]Ga-HA-DOTA-TATE (mean RA SUVmean 1.88 vs. 0.36, p < 0.001), while [68Ga]Ga-HA-DOTA-TATE had a significantly higher liver uptake (mean liver SUVmean 7.54 vs. 2.39, p < 0.001). Vascular uptake (as measured by both SUVmax and TBRliver) was significantly higher in [18F]FDG than [68Ga]Ga-HA-DOTA-TATE scans in every vascular territory (p < = 0.05 for all comparisons), including index vessels (SUVmax 4.04 vs. 1.91, p = 0.01, TBRliver 1.73 vs. 0.27, p < 0.001). Conclusion In this pilot study of patients with active GCA, the arterial uptake of [68Ga]Ga-HA-DOTA-TATE was lower and less conspicuous compared to [18F]FDG. While further evaluation in larger cohorts is needed, a clear advantage of [68Ga]Ga-HA-DOTA-TATE over [18F]FDG for detecting vascular inflammation in GCA was not identified. Trial registration, ClinicalTrials.gov NCT 03812302, registered 2019-01-18, URL: <a href="https://clinicaltrials.gov/search?cond=dotatate%20%26;term=giant%20cell%20arteritis">https://clinicaltrials.gov/search?cond=dotatate%20%26;term=giant%20cell%20arteritis</a>.

Comparison of [¹⁸F]fluorodeoxyglucose and [⁶⁸Ga]Gallium DOTA-TATE in patients with active giant cell arteritis

期刊论文
出版模式：

开放获取
发表日期：

2025年3月1日

查看全文

Alison H. Clifford,
Jonathan Abele,
Ryan Hung,
Frank Wuest,
Jan Andersson,
Susan Pike,
Elaine Yacyshyn,
Eric Lenza,
Glen Jickling,
Paolo Raggi,
Jan Willem Cohen Tervaert

摘要

Purpose

[¹⁸F]Fluorodeoxyglucose (FDG) is widely used in PET/CT imaging to detect large vessel vasculitis in giant cell arteritis (GCA), but its performance is suboptimal in patients receiving glucocorticoids. We aimed to compare [⁶⁸Ga]Ga-HA-DOTA-TATE, a somatostatin 2-analogue tracer, to [¹⁸F]FDG in a pilot study of patients with GCA.

Methods

Eight patients with active GCA were prospectively, sequentially scanned with both [¹⁸F]FDG PET/CT and [⁶⁸Ga]Ga-HA-DOTA-TATE PET/CT imaging. Images were evaluated by 2 blinded nuclear medicine specialists. Tracer uptake was assessed in 8 vascular territories using SUVmax, and target-background ratios (TBR) were calculated using both right atrium (TBR_RA) and liver mean (TBR_liver). Mean SUVmax and TBR of individual vascular territories and index vessels were compared.

Results

The patient median age was 71.5 years (range 64–82), and 4 (50%) were women. Active vasculitis (≥ grade 2 visual uptake in large vessels) was present in 62.5% of [¹⁸F]FDG scans. [¹⁸F]FDG scans had higher RA background activity than [⁶⁸Ga]Ga-HA-DOTA-TATE (mean RA SUVmean 1.88 vs. 0.36, p < 0.001), while [⁶⁸Ga]Ga-HA-DOTA-TATE had a significantly higher liver uptake (mean liver SUVmean 7.54 vs. 2.39, p < 0.001). Vascular uptake (as measured by both SUVmax and TBR_liver) was significantly higher in [¹⁸F]FDG than [⁶⁸Ga]Ga-HA-DOTA-TATE scans in every vascular territory (p < = 0.05 for all comparisons), including index vessels (SUVmax 4.04 vs. 1.91, p = 0.01, TBR_liver 1.73 vs. 0.27, p < 0.001).

Conclusion

In this pilot study of patients with active GCA, the arterial uptake of [⁶⁸Ga]Ga-HA-DOTA-TATE was lower and less conspicuous compared to [¹⁸F]FDG. While further evaluation in larger cohorts is needed, a clear advantage of [⁶⁸Ga]Ga-HA-DOTA-TATE over [¹⁸F]FDG for detecting vascular inflammation in GCA was not identified.

Trial registration, ClinicalTrials.gov

NCT 03812302, registered 2019-01-18, URL: https://clinicaltrials.gov/search?cond=dotatate%20%26;term=giant%20cell%20arteritis.

Comparison of [18F]fluorodeoxyglucose and [68Ga]Gallium DOTA-TATE in patients with active giant cell arteritis

摘要

Comparison of [¹⁸F]fluorodeoxyglucose and [⁶⁸Ga]Gallium DOTA-TATE in patients with active giant cell arteritis